ICD code T45.625D – Adverse effect of hemostatic drug

Found our content helpful?

Key takeaways

T45.625D is the billable ICD-10-CM code for adverse effect of hemostatic drug, subsequent encounter, valid for FY 2016 through FY 2026.

The 7th character ‘D’ means active treatment is complete and the patient is in routine follow-up care, not that this is a second visit.

Adverse effect coding applies when the drug was given correctly and still caused harm, and the condition it caused leads the claim.

Coagulation factors and desmopressin are not indexed to T45.625, so a factor reaction takes T45.8X5D rather than this code.

Where a payer or state law asks for an external cause code, Y44.9XXD is the one that pairs with T45.625D.

Practice management software like Pabau flags a missing or mismatched code pair before the claim leaves the practice.

T45.625D code details at a glance

The table below captures every field a billing team or EMR needs for ICD-10 code T45.625D.

Per the CMS ICD-10 codes page, T45.625D sits in the broader T45 category alongside the poisoning and underdosing codes for the same drug class. Those three labels decide both the code and its position on the claim.

Why ‘D’ means treatment phase, not visit count

‘D’ means the active treatment phase of the condition is over and the patient is receiving routine care, healing checks, or follow-up management. It does not mean the patient’s second visit. ICD-10-CM Official Guidelines Section I.C.19.a covers how 7th characters apply in Chapter 19, and the count of encounters never enters into it.

A patient seen on three consecutive days in the ER for tranexamic acid thrombosis takes the ‘A’ code all three times. Active treatment is still under way. The same patient returning two weeks later for a thrombosis check takes ‘D’. Other chapters run the same logic, as S72.91XG shows on a fracture claim.

For sequela encounters, the residual condition code is sequenced first and T45.625S follows it, per ICD-10-CM Guidelines Section I.C.19. A sequela code from another chapter such as S69.91XS behaves the same way. The three codes differ only in treatment phase, and all three share one claim order.

Adverse effect vs. poisoning vs. underdosing in ICD-10

Adverse effect, poisoning, and underdosing describe three separate events, and each one codes to a different subcategory. The chart note decides which applies, not how severe the reaction was.

ICD-10-CM Official Guidelines Section I.C.19.e.5(a) covers adverse effects. It sequences the nature of the adverse effect as the principal diagnosis, with T45.625D listed after it. Poisoning runs the other way round, and its rule sits in Section I.C.19.e.5(b). Coding a correctly administered drug as a poisoning misstates what happened in the chart, and a payer audit picks up that kind of mismatch.

Which hemostatic drugs fall under T45.625D

The ICD-10-CM Alphabetic Index points to T45.625 for adverse effects of agents that promote hemostasis, meaning blood clotting. Chart notes often describe a drug reaction without ever using the word hemostatic. Knowing the drug classes prevents a slide into a vaguer T45 code.

The substances behind most T45.625D claims, according to the CDC’s ICD-10-CM Table of Drugs and Chemicals, are these:

• Antifibrinolytics: tranexamic acid (Cyklokapron, Lysteda) and aminocaproic acid (Amicar). Both prevent fibrin breakdown and carry a documented thrombosis risk.
• Fibrin sealants: topical agents such as Tisseel and Evicel, applied during surgery to control bleeding at the site.
• Systemic hemostatics not named elsewhere in the index: the index routes these to T45.625 rather than to a drug-specific entry.

Drugs that look hemostatic but code elsewhere

Two drug groups are treated as hemostatics at the bedside and are indexed somewhere else entirely. Coding them to T45.625D is the error a hematology or hemophilia claim runs into most often.

• Coagulation factors: the CDC table indexes Factor VIII and Factor IX to T45.8X5, and Factor IX complex to T45.7X5. At a follow-up visit those become T45.8X5D and T45.7X5D. On the drug side, Factor VIIa bills under J7189.
• Desmopressin (DDAVP): it releases stored von Willebrand factor, so it reads as a hemostatic. Its adverse effect codes to T38.895 with the other hormones and synthetic substitutes. The factor concentrate used for the same indication bills under J7187.

Thrombosis is the adverse effect coded most often across this drug class, particularly for the antifibrinolytics. The code for the thrombotic event is sequenced first, with T45.625D after it. For an acute deep vein thrombosis of the right lower extremity that first code is I82.401. The femoral-vein-specific codes are I82.411, I82.412, and I82.413. Check the drug’s FDA label for its adverse effect profile before finalizing the note.

Parent code hierarchy: The T45.625 family

T45.625 is a non-billable parent code, and submitting it without a 7th character will be rejected. The full hierarchy leading to T45.625D runs like this:

• S00-T88: Injury, poisoning, and certain other consequences of external causes
• T36-T50: Poisoning, adverse effects and underdosing of drugs, medicaments and biological substances
• T45: Poisoning, adverse effect and underdosing of primarily systemic and hematological agents, not elsewhere classified
• T45.6: Poisoning, adverse effect and underdosing of fibrinolysis-affecting drugs
• T45.62: Poisoning, adverse effect and underdosing of hemostatic drugs
• T45.625: Adverse effect of hemostatic drug (non-billable; 7th character required)
• T45.625A: Adverse effect of hemostatic drug, initial encounter
• T45.625D: Adverse effect of hemostatic drug, subsequent encounter
• T45.625S: Adverse effect of hemostatic drug, sequela

Sitting inside T45.6 tells you the scope: fibrinogen, fibrinolytic inhibitors, and related agents all land here. Anyone learning medical billing from the ground up meets this block structure early. Sequencing rules attach to the block rather than the individual code.

External cause codes to pair with T45.625D

An external cause code from the Y40-Y59 range names the drug responsible for the adverse effect. Reporting it is not mandated nationally. Per ICD-10-CM Official Guidelines Section I.C.20.a, no national requirement covers Chapter 20 external cause reporting. State law or a payer contract can still ask for it.

Most billing teams add it anyway, and pair it consistently on every claim. It adds one code to the claim, and it identifies the drug for anyone reviewing the record later. Consistency is also what keeps medical billing compliance defensible across a mixed payer list. The codes that apply to hemostatic drugs are these:

Take a follow-up visit for DVT monitoring after a tranexamic acid reaction. The code set reads I82.401 for the acute thrombosis, then T45.625D, then Y44.9XXD where the payer wants an external cause code. Pabau’s Claim.MD integration validates each set against payer edits before submission, so an incomplete pair is caught in the practice rather than at the clearinghouse.

What the chart note must document

A T45.625D claim rests on four statements in the note. Each one answers a question a payer or an auditor will otherwise ask later.

• The drug and how it was given: Name the hemostatic drug, the dose, and the route. That is what separates an adverse effect from a poisoning.
• The reaction the drug caused: Name the condition, because that condition leads the claim rather than T45.625D.
• The treatment phase: State that active treatment has ended and this visit is follow-up, monitoring, or a healing check.
• The link between drug and reaction: Say the drug caused the condition. A reviewer should not have to infer it from the medication list.

The phase statement is the one most often missing. A note that never says follow-up leaves the ‘D’ unsupported, and the reviewer reads the visit as active treatment. When claims on this code pend, the remark codes usually point back at one of the four statements. Reading them against the denial codes list shows which one your notes keep leaving out.

Coding errors to avoid with T45.625D

Denials on this code follow a predictable pattern, and six mistakes account for most of them. Each one is visible in the chart note before the claim goes out.

• Using T45.625D when the encounter is still initial: If the patient is still in active treatment, use T45.625A. Submitting ‘D’ during active treatment contradicts the clinical documentation.
• Coding an adverse effect as poisoning: If the chart confirms correct administration, T45.625D is right. A poisoning code says the dose, drug, or route was wrong, which the note does not support.
• Omitting the external cause code: T45.625D without a Y44 code may fail payer-specific edits, even though no national rule requires one. Check what your largest payers expect and apply it consistently.
• Submitting the parent code T45.625: T45.625 without a 7th character is non-billable, so every claim carrying it rejects. Always extend to T45.625A, T45.625D, or T45.625S.
• Sequencing the adverse effect code first: Per Guidelines Section I.C.19.e.5(a), the clinical condition is the principal diagnosis and T45.625D is secondary. Reversing the two invites a claim edit.
• Using T45.625D for a sequela encounter: A late effect takes T45.625S instead. Chronic venous insufficiency from an earlier drug-induced clot is a sequela, and the residual condition leads the claim.

A run of denials on this code usually traces back to one of the six. Reading them as a batch, the way a structured denial management review does, surfaces the encounter-type mismatch or the missing external cause code fast. Fixing it at the point of documentation is what turns the next batch into clean claims.

Related ICD-10 codes you may need

T45.625D rarely appears on a claim by itself. Coders working with hemostatic drug reactions reach for the sibling codes and the neighboring T45 codes below. The AAPC ICD-10-CM code lookup confirms each one for the applicable fiscal year.

The icd10data code entry also records two edits worth knowing: T45.625D is exempt from present-on-admission reporting, and it is not acceptable as a principal diagnosis. On an inpatient claim it therefore sits as a secondary code, which is where its effect on revenue cycle management is easiest to miss.

How Pabau keeps adverse effect claims paired correctly

In most practices, a mis-sequenced adverse effect code gets caught the slow way. The denial arrives, someone reopens the chart note, and the corrected claim goes back out three weeks later. The check happens after the payer has already said no.

Practice management software like Pabau moves that check to the point of documentation. The coded diagnosis lives on the same client record as the treatment note. A coder can see how the drug was prescribed and given before choosing between an adverse effect and a poisoning code. Pabau’s claims management software then keeps the condition code, the T-code, and the external cause code together as one set.

That matters most in the services that give these drugs day to day. Surgical suites in plastic surgery practices use fibrin sealants at the wound site, and IV therapy practices run tranexamic acid and factor concentrates.

The outcome your team feels is fewer rework cycles. Claims leave with the right 7th character and the right lead diagnosis. The follow-up visit gets paid first time, and nobody spends Friday afternoon re-reading three-week-old notes.

Reduce ICD-10 coding errors with Pabau

Pabau’s claims management tools integrate with Claim.MD to validate ICD-10 code pairs before submission, reducing denials on adverse effect and hemostatic drug claims. See how it works for your billing team.

Book a demo

Conclusion

Two decisions carry this code. Which treatment phase the patient is in, and which diagnosis leads the claim. Get both right and T45.625D pays without argument. Get either wrong and the denial lands before anyone has looked at the chart note.

Check the drug against the index before you reach for this code, because coagulation factors and desmopressin sit elsewhere. The external cause code is the one judgment call left. Find out what your largest payers expect, then apply the same house rule to every claim. Inconsistency costs more than either choice would.

Book a demo to see how Pabau keeps the diagnosis, the treatment note, and the claim in one record for your billing team.

Continue your research

Want another worked example of subsequent encounter coding? S82.226G applies the same 7th character logic to a fracture claim, including the delayed healing character.

Coding a residual condition instead of a follow-up visit? T22.342S shows how the sequela 7th character works on a burn claim, and which code leads there.

Billing the drug as well as the diagnosis? J7189 covers units, documentation, and payer expectations on the HCPCS side of a factor claim.

Need the note itself to support the code? Our progress note template gives you a structure that records the drug, the reaction, and the treatment phase.

Frequently asked questions